Perrigo Company plc (PRGO) — ESG & Values Scores

Environment story

Perrigo has disclosed a net-zero target of 2040, which exceeds the 2045 threshold penalty but falls short of 2035 best practice. Scope 1 and Scope 2 emissions data are not quantitatively disclosed in the 10-K; Scope 3 emissions status is undisclosed, triggering a 15-point deduction. The company states commitment to renewable energy investment and EV fleet conversion for international operations but provides no verified decarbonization infrastructure metrics or renewable percentage. The 10-K does not report major environmental remediation liabilities or toxic-waste controversies. However, the company's reliance on disclosure frameworks (TCFD, SASB, GRI) without specific quantified progress metrics, combined with undisclosed Scope 3 data representing supply-chain emissions in a consumer-goods/pharma model, suggests greenwashing risk. No evidence of carbon-offset reliance detected, but lack of granular operational decarbonization data prevents higher scoring.

Criticisms on file

FDA Warning Letter – Wisconsin Infant Formula Facility (August 2023). In response to FDA observations, company shortened production campaigns, increased cleaning frequency, and implemented enhanced quality procedures, resulting in increased production costs and reduced production volumes. Company expects higher compliance costs to continue.
Source: Perrigo 10-K Item 1A Risk Factors, Item 1 Business - Government Regulation and Pricing
Undisclosed Scope 3 emissions and lack of quantitative baseline data. 10-K does not provide Scope 1, Scope 2, or Scope 3 absolute or intensity metrics, making progress tracking and comparability impossible.
Source: Perrigo 10-K Item 1 Business - OUR SUSTAINABILITY AND ENVIRONMENTAL, SOCIAL AND GOVERNANCE ESG STRATEGY
EU Green Deal & Climate Regulation Risk. Company acknowledges 55% emissions reduction by 2030 and 90% by 2040 regulatory targets set by European Commission (July 2021, February 2024). Growing focus on environmental impact of self-care products, ingredients, packaging, manufacturing, and disposal could lead to new requirements and restrictions.
Source: Perrigo 10-K Item 1A Risk Factors - Operational Risks
Middle East Conflict Supply Chain Exposure. Company sources API and finished goods from Israel (Omeprazole and others). Potential disruption to in-country logistics and freight. Company has engaged alternate suppliers but conflict remains fluid.
Source: Perrigo 10-K Item 1A Risk Factors - Operational Risks

Disclosed initiatives

Electric Vehicle Fleet Conversion

International business transitioning to electric vehicle fleets as part of emissions-reduction strategy.

Operational scope reduction; timeline and percentage adoption not disclosed.
Renewable Energy Investment

Company states commitment to investing in renewable energy as part of net-zero pathway.

Intended to reduce Scope 2 emissions; no quantified renewable percentage or MWh targets disclosed.
Packaging Redesign & Circular Economy

Transitioning to reusable, recyclable, and compostable packaging; reducing packaging weight and innovating materials.

Scope 3 product-use emissions mitigation potential; no lifecycle-assessment data or waste-reduction targets provided.
Production Footprint Minimization

Redesigning products and manufacturing to minimize production footprint.

Reduces Scope 1 direct emissions; specific infrastructure investments not detailed.

Social story

Perrigo reports approximately 8,100 full-time and part-time employees across 31 countries; 17.5% are covered by collective bargaining agreements as of December 31, 2025. Company describes commitment to 'belonging' culture, diversity at board and executive levels, and competitive Total Rewards packages. No CEO-to-median-worker pay ratio disclosed in the 10-K, preventing calculation of a key Social metric. No documented union-suppression activities or major strikes within 24 months are disclosed. The 10-K acknowledges past FDA warning for infant formula facility and commits to remediation but does not report facility-level safety incidents or Lost Time Injury Rate. Leadership diversity targets stated qualitatively ('progress in increasing representation') but no percentage metrics provided for women or underrepresented groups in executive/board roles. Supply-chain human-rights audits are mentioned ('regular risk assessments and audits'), but no specific audit findings, remediation data, or third-party certification (e.g., Responsible Care) are disclosed. Turnover rate is not reported. Overall, the company demonstrates strong rhetoric around inclusion and safety but lacks quantitative transparency on pay equity, leadership diversity metrics, and labor-relations history.

Criticisms on file

FDA Warning Letter & Manufacturing Compliance (August 2023). Wisconsin infant formula facility received FDA observations resulting in shortened production campaigns, increased cleanings, enhanced testing, and additional infrastructure investments. Extraordinary costs incurred; production volumes reduced; higher ongoing compliance costs expected. Company states 'all sites have returned to reliable, quality-assured production.'
Source: Perrigo 10-K Item 1A Risk Factors, Item 1 Business
Undisclosed CEO-to-Median-Worker Pay Ratio. No pay-ratio disclosure in 10-K prevents assessment of executive compensation equity.
Source: Perrigo 10-K Item 1 Business - Human Capital Resources
No Quantified Leadership Diversity Metrics. While company claims 'progress in increasing representation at board and executive levels,' specific percentage composition for women and underrepresented minorities is not disclosed.
Source: Perrigo 10-K Item 1 Business - Human Capital Resources, People & Communities
Supply-Chain Labor Practices Undisclosed. Company commits to human-rights audits and responsible sourcing but does not disclose audit findings, remediation actions, or third-party verification of compliance with living-wage, child-labor, or forced-labor standards.
Source: Perrigo 10-K Item 1 Business - Responsible Sourcing, Human Rights

Disclosed initiatives

Culture of Belonging & Inclusion

Company emphasizes 'belonging' as strategic enabler; implementing structured communications, feedback mechanisms, and annual career conversations. Three Core Values: 'We Care Deeply,' 'We Do the Right Thing,' 'We Play to Win.'

Intended to improve engagement, retention, and workplace culture; no quantified engagement-survey results or turnover benchmarks provided.
Board and Executive Diversity Advancement

Company reports 'progress in increasing representation at board and executive levels' to reflect consumer diversity globally.

Diversity composition percentages not disclosed; claimed alignment with consumer demographics.
HEALTHYyou Well-being Program

Global employee wellness program supporting colleagues and families; recognized externally with 'Best and Brightest in Wellness™ Award' every year since 2017.

Employee health and mental-wellness support; no participation metrics or health-outcome data disclosed.
Leadership Development & Talent Pipeline

Invested in global framework of core behaviors ('Perrigo at Our Best'), GROWyou personal development curriculum, 24/7 on-demand learning content, and high-potential identification process.

Builds organizational capability and succession planning; no measurable promotion rates or retention impact reported.
Modern Slavery & Human Rights Commitment

Company maintains ethical standards for all contractors, suppliers, and third parties. Conducts regular risk assessments and audits of supply chain; committed to fight against modern slavery, child labor, and unsafe working conditions.

Supply-chain governance framework; no audit reports, findings, or third-party verification disclosed.
Employee Assistance Program (EAP)

Global EAP designed to meet diverse needs of colleagues across multiple identities, cultures, and languages.

Mental-health and behavioral-support resource; utilization and effectiveness metrics not reported.

Governance story

Perrigo reports that 'specific committees' of the Board provide focused review of sustainability and climate-related risks, but detailed board independence percentage is not quantified in the 10-K. The company is incorporated in Ireland and is a public limited company (plc) with a single-share class structure (ordinary shares); no evidence of dual-class voting or unequal shareholder rights is disclosed. Annual lobbying expenditure is not reported. The company discloses it is subject to antitrust enforcement risk ('Increased scrutiny on pricing practices and competition, including antitrust enforcement activity by government agencies and class action litigation') but does not report active ongoing antitrust proceedings. Multiple product-safety recalls and FDA compliance actions (e.g., warning letter for infant formula facility, nitrosamine impurities guidance) are referenced but not characterized as 'active significant regulatory proceedings' in the governance context. No evidence of active litigation specifically related to antitrust, consumer fraud, or financial-reporting consent decrees is disclosed. The 10-K does not disclose lobbying expenditures targeting environmental deregulation or consumer-protection rollbacks. Overall, governance structure appears standard for a large-cap plc, but transparency on board composition, independence metrics, and lobbying is limited.

Criticisms on file

Antitrust Enforcement Risk. Company discloses 'Increased scrutiny on pricing practices and competition, including antitrust enforcement activity by government agencies and class action litigation' as material risk. No active specific proceedings disclosed, but general exposure acknowledged.
Source: Perrigo 10-K Item 1A Risk Factors - Litigation and Insurance Risks
FDA Regulatory Actions & Product Recalls. Warning letter for Wisconsin infant formula facility (August 2023); nitrosamine impurity guidance compliance ongoing; potential codeine product reclassification in Ireland (final opinion expected 2026); Operation Stork Speed regulatory initiative impacting infant formula compliance. No quantified fines disclosed, but material compliance costs acknowledged.
Source: Perrigo 10-K Item 1A Risk Factors - Operational Risks
Consumer Product Safety & Liability Exposure. Company discloses risks of product contamination, recalls, and product-liability litigation. FDA may require labeling modifications, testing restrictions, or product withdrawal. No active litigation disclosed, but systemic risk acknowledged.
Source: Perrigo 10-K Item 1A Risk Factors - Operational Risks
Data Privacy & Cybersecurity Compliance. Company subject to GDPR, CCPA, and other state/national privacy laws. Notes 'immaterial' business disruption and data loss from phishing and business-email-compromise attacks. Expects heightened cybersecurity risks from AI adoption. No material fines disclosed, but compliance-cost escalation expected.
Source: Perrigo 10-K Item 1A Risk Factors - Operational Risks
Shareholder Activist Risk & Investor Litigation. Company acknowledges heightened susceptibility to investor lawsuits following stock-price declines and activist campaigns. Company has been named in past lawsuits; no specific active proceedings disclosed.
Source: Perrigo 10-K Item 1A Risk Factors - Operational Risks

Disclosed initiatives

Board-Level ESG Oversight

Board of Directors maintains responsibility for overseeing all major enterprise risks, including ESG matters. Specific committees provide focused review of sustainability and climate-related risks.

Governance structure for ESG integration; detailed board-committee composition and independence metrics not disclosed.
Management-Level Sustainability Governance

Executive Leadership Team and Vice President Global Ethics, Privacy & Sustainability lead management oversight. Sustainability professionals embedded across key business functions.

Cross-functional approach to sustainability decision-making and operational practices; effectiveness not quantified.
Internal Audit & Environmental Compliance

Company conducts periodic internal audits related to environmental, health, and safety requirements; maintains regulatory registers of compliance obligations; performs periodic self-assessments for each manufacturing site.

Compliance monitoring framework; no material remediation liabilities outstanding; no audit findings disclosed.
Risk Management Framework

Company aligns with established frameworks: TCFD (Task Force on Climate-related Financial Disclosures), SASB (Sustainability Accounting Standards Board), and GRI (Global Reporting Initiative).

Structured disclosure and risk-assessment approach; transparency limited by lack of quantified metrics.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Perrigo Company plc. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Perrigo Company plc in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)